Effects of 7~11 cycles adjuvant FOLFOX chemotherapy on the prognosis of patients with stage III colon cancer

다국어 초록 (Multilingual Abstract)

Adjuvant fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy for 6 months is the standard treatment of stage III colon cancer to improve patient survival. Recent studies have shown that restricting the treatment to 3 months to reduce toxicity negatively affects the outcome. However, the effect of FOLFOX treatment for a duration of between 3 and 6 months(7~11 cycles) on survival is not known. The effect of a reduced duration of FOLFOX chemotherapy on the prognosis of stage III colon cancer was examined. The 5-year disease-free survival in patients receiving 7~11 cycles of FOLFOX was lower than those receiving 12 cycles(72.9% vs. 87%, respectively). Patients receiving 7~11 cycles who had a bowel obstruction at diagnosis had a significantly higher recurrence rate (66.7% vs. 15.0%) and shorter median disease-free survival (24.7 months vs. not reached) than those receiving 12 cycles. Among patients receiving 12 cycles of FOLFOX, there was no difference in the outcome between those with and those without intestinal obstructions at diagnosis. These results suggest that the completion of 12 cycles FOLFOX chemotherapy is important to improve the patient's prognosis, especially for with intestinal obstructions at diagnosis.

참고문헌 (Reference)

1 Andre T, "Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage III colon cancer: disease-free survival results from a randomized, open-label, international duration evaluation of adjuvant (IDEA) France, Phase III Trial" 36 : 1469-1477, 2018

2 O̓Connell MJ, "Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer" 16 : 295-300, 1998

3 Lonardi S, "Phase III trial comparing 3~6 months of adjuvant FOLFOX4/XELOX in stage II~III colon cancer : safety and compliance in the TOSCA trial" 27 : 2074-2081, 2016

4 Andre T, "Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1" 25 : 3732-3738, 2007

5 Cersosimo RJ, "Oxaliplatin-associated neuropathy : a review" 39 : 128-135, 2005

6 백경기, "Oxaliplatin-Induced Chronic Peripheral Neurotoxicity:A Prospective Analysis in Patients with Colorectal Cancer" 대한암학회 42 (42): 185-190, 2010

7 Andre T, "Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer" 350 : 2343-2351, 2004

8 Andre T, "Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial" 27 : 3109-3116, 2009

9 Jemal A, "Global cancer statistics" 61 : 69-90, 2011

10 Grothey A, "Duration of Adjuvant Chemotherapy for Stage III Colon Cancer" 378 : 1177-1188, 2018

11 Haller DG, "Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer" 29 : 1465-1471, 2011

12 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015" 대한암학회 50 (50): 303-316, 2018

13 김수현, "A Prospective Study of Chronic Oxaliplatin-Induced Neuropathy in Patients with Colon Cancer: Long-Term Outcomes and Predictors of Severe Oxaliplatin-Induced Neuropathy" 대한신경과학회 14 (14): 81-89, 2018